- David A. Cory, RPh, MBA, President and Chief Executive Officer
- Brian Murphy, MD, MPH, MBA, Chief Medical Officer
- Jeffrey S. Glenn, MD, PhD, Director, Founder
- Ingrid C. Choong, PhD, Director, Chemistry
- Curtis L. Scribner, MD, Vice President, Regulatory
- Kevin R. Kaster, JD, Vice President, Patents and Licensing
David Cory is an entrepreneur and industry veteran with a 25-year track record of experience in large pharmaceutical, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record building and guiding private and public companies, leading preclinical and clinical development through regulatory approvals, commercial operations, financing private and public companies, and creating liquidity for investors in multiple company IPOs and acquisitions.
Cory was President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS company, and was responsible for venture financing and management of U.S. and Canadian operations. Prestwick was acquired by Biovail Pharmaceuticals for $160 million in 2008. Cory was Co-Founder and Chief Commercial Officer at CoTherix, an Orphan Pulmonary Hypertension company, and was responsible for co-leading product in-licensing and venture financing. CoTherix was acquired by Actelion for $425 million in 2006. Cory was Senior Vice President of Commercial Operations at InterMune, participated in the ITMN IPO, was responsible for building and managing the companyís commercial organization, a key executive involved in the acquisition of 4 products and raising over $400 million in capital. Cory spent the first 12 years of his career in business development and commercial operating positions of increasing responsibility at Upjohn and Glaxo, Glaxo Wellcome, and Glaxo Smith Kline across CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, directing over 10 pharmaceutical product launches and the commercialization of over 20 brands.
David Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masterís Degree in Business Administration from the University of Maryland.
Dr. Murphy has 15 years experience in drug development and evaluation, both from the academic and industry perspective. He most recently served as the Chief Medical Officer of Epiphany Biosciences. Previously, Dr. Murphy was Chief Medical Officer at Valeant Pharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs and Pharmacovigilance. Dr. Murphy also served as Medical Director, then Vice President of Marketing and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). Prior to InterMune, Dr. Murphy was Medical Director of North America for Antivirals/Interferons at Hoffmann-LaRoche.
Prior to joining industry, Dr. Murphy was Assistant Professor of Medicine at New York Medical College and was Director of the Clinical Strategies Programs at St. Vincent's Hospital in New York City, the lead hospital of the Catholic Healthcare Network of New York. In addition to patient care and teaching, his research interests focused on the treatment of HIV and the viral hepatitides, including serving on advisory boards, being a clinical trial investigator, making network television appearances and serving as a reviewer for professional publications. Dr. Murphy is board-certified in internal medicine and completed his residency in internal medicine at Tufts-New England Medical Center and served as Chief Medical Resident in the Boston University program. He went on to complete parallel fellowship tracts at Harvard Medical School, one in internal medicine/clinical epidemiology at the Massachusetts General Hospital and the other in medical ethics addressing issues of distributive justice and access to care. He is a member of Alpha Omega Alpha, the national honor medical society.
Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.
Dr. Glenn is an Associate Professor of Medicine, Gastroenterology & Hepatology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering.
Dr. Glenn is an author on over 50 scientific articles and book chapters, is an inventor on over 30 issued and pending patent applications, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. His primary research interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies.
Dr. Glenn’s work has focused on the function and cell biology of the hepatitis C virus (HCV) non-structural proteins, and has identified a collection of novel antiviral targets within HCV that can form the basis for new potential antiviral strategies. Dr. Glenn discovered the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses including as a trigger of virus assembly and a target for a promising antiviral treatment. Other interests include exploitation of hepatic stem cells, development of a small animal model for HCV, and engineered human liver tissues.
Dr. Glenn received his undergraduate degree from the University of California, Berkeley summa cum laude in Biochemistry and French Civilization, and both a PhD in Biochemistry and Biophysics and MD from the University of California, San Francisco Medical Scientist Training Program. Dr. Glenn completed an internship and residency in internal medicine, as well as a fellowship in gastroenterology, at Stanford University's School of Medicine.
Ingrid Choong has 12 years of experience in biotechnology, and most recently served as Group Leader at Sunesis Pharmaceuticals, focusing on developing anti-inflammation and anti-cancer agents. While at Sunesis, Dr. Choong co-led a collaboration with Johnson and Johnson Pharmaceutical Research and Development, resulting in the successful transition of the Cathepsin S program from early discovery into development. In addition, Dr. Choong co-led a second generation small-molecule inhibitor program against cyclin-dependent kinases (CDKs) 2, 7 and 9, as well as several other early discovery-staged small molecule programs.
Dr. Choong did her undergraduate work at the California Institute of Technology in Chemistry and holds a PhD in Chemistry from the University of California, Berkeley.
Dr. Scribner has more than 25 years of drug development and regulatory affairs experience. He spent 11 years at the FDA in the Center for Biologics as a medical officer with wide experience reviewing non-clinical, CMC, clinical, and IND/BLA regulatory systems, including 2.5 years as the Deputy Director of the Office of Blood. He also was the Senior Regulatory Consultant for Quintiles Consulting, Chief Regulatory Office for Intarcia Therapeutics and he is now the Senior Vice President for Medical and Regulatory Affairs for RRD International. Dr. Scribner is a board certified Internist with post-doctorial training in Immunology and Rheumatology at the NIH.
Kevin Kaster has 20 years of experience in biotechnology and large pharma with an established track record of developing effective patent and licensing strategies for important technologies and drug products.
Kevin Kaster most recently served as Vice President Corporate Development for Threshold Pharmaceuticals, a public company focused on developing anti-cancer agents. Previously, Kaster was Vice President Intellectual Property for Kosan Biosciences, a public company acquired by BMS in 2008 with geldanamycin and epothilone anti-cancer agents. Kaster also previously managed the patent portfolios of Geron Corporation (telomerase and human embryonic stem cell technologies) and Affymax/Affymetrix (combinatorial chemistry and DNA chip technologies) as well as the PCR technology patent portfolio of Cetus Corporation. Kaster began his career at Eli Lilly and Company, first as a research scientist and then as a patent technician.
Kevin Kaster is a graduate of the Indiana University School of Law and a graduate of Vanderbilt University with a BS in Chemistry and Molecular Biology.